NZ298878A - Use of melatonin to treat addiction to benzodiazepines - Google Patents

Use of melatonin to treat addiction to benzodiazepines

Info

Publication number
NZ298878A
NZ298878A NZ298878A NZ29887896A NZ298878A NZ 298878 A NZ298878 A NZ 298878A NZ 298878 A NZ298878 A NZ 298878A NZ 29887896 A NZ29887896 A NZ 29887896A NZ 298878 A NZ298878 A NZ 298878A
Authority
NZ
New Zealand
Prior art keywords
melatonin
benzodiazepines
treat addiction
addiction
treat
Prior art date
Application number
NZ298878A
Other languages
English (en)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of NZ298878A publication Critical patent/NZ298878A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ298878A 1995-02-01 1996-01-29 Use of melatonin to treat addiction to benzodiazepines NZ298878A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (1)

Publication Number Publication Date
NZ298878A true NZ298878A (en) 1999-05-28

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ298878A NZ298878A (en) 1995-02-01 1996-01-29 Use of melatonin to treat addiction to benzodiazepines

Country Status (22)

Country Link
JP (1) JP4516159B2 (sk)
CN (1) CN1083263C (sk)
AT (1) AT408188B (sk)
AU (1) AU695366B2 (sk)
BG (1) BG62876B1 (sk)
BR (1) BR9607169A (sk)
CZ (1) CZ291349B6 (sk)
DK (1) DK176081B1 (sk)
EE (1) EE03384B1 (sk)
FI (1) FI119586B (sk)
IS (1) IS1980B (sk)
LU (1) LU90118B1 (sk)
LV (1) LV11940B (sk)
MD (1) MD1716C2 (sk)
NO (1) NO312814B1 (sk)
NZ (1) NZ298878A (sk)
PL (1) PL183148B1 (sk)
SI (1) SI9620022A (sk)
SK (1) SK284521B6 (sk)
TR (1) TR199700723T1 (sk)
TW (1) TW483757B (sk)
WO (1) WO1996023496A1 (sk)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201219B1 (pl) 2000-01-05 2009-03-31 Neurim Pharma 1991 Zastosowanie melatoniny do wytwarzania leku
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
BR112015014619A2 (pt) 2012-12-18 2017-07-11 Vanda Pharmaceuticals Inc tratamento de transtornos do ritmo circadiano
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
AU2016426598C1 (en) * 2016-10-31 2024-02-08 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000073I1 (de) * 1991-05-09 2008-01-31 Neurim Pharma 1991 Melatonin enthaltene Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
DK176081B1 (da) 2006-04-18
IS4532A (is) 1997-07-25
MD970254A (en) 1999-05-31
CZ240597A3 (cs) 1998-01-14
SK284521B6 (sk) 2005-05-05
LU90118B1 (fr) 1997-11-13
NO312814B1 (no) 2002-07-08
TR199700723T1 (xx) 1998-02-21
FI119586B (fi) 2009-01-15
JP4516159B2 (ja) 2010-08-04
WO1996023496A1 (en) 1996-08-08
CZ291349B6 (cs) 2003-02-12
NO973531D0 (no) 1997-07-31
DK89697A (da) 1997-07-30
AU4457496A (en) 1996-08-21
LV11940A (lv) 1998-01-20
ATA901396A (de) 2001-02-15
LV11940B (en) 1998-05-20
PL183148B1 (pl) 2002-05-31
CN1172431A (zh) 1998-02-04
BG101803A (en) 1998-04-30
BR9607169A (pt) 1997-11-11
MD1716B2 (en) 2001-08-31
FI973185A (fi) 1997-09-30
MX9705856A (es) 1998-07-31
JPH10513177A (ja) 1998-12-15
PL321630A1 (en) 1997-12-08
FI973185A0 (fi) 1997-07-31
CN1083263C (zh) 2002-04-24
SK103097A3 (en) 1998-01-14
IS1980B (is) 2005-01-14
SI9620022A (sl) 1998-10-31
MD1716C2 (ro) 2002-02-28
AU695366B2 (en) 1998-08-13
NO973531L (no) 1997-09-30
AT408188B (de) 2001-09-25
TW483757B (en) 2002-04-21
EE9700166A (et) 1998-02-16
BG62876B1 (bg) 2000-10-31
EE03384B1 (et) 2001-04-16

Similar Documents

Publication Publication Date Title
HUP9900065A3 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
GB2335153B (en) Treatment of water
GB9526560D0 (en) Use of 2-Amino-Heterocycles
EP0795035A4 (en) SKIN TREATMENT
EP0735054A3 (en) Process for the treatment of modified polymers
NZ298878A (en) Use of melatonin to treat addiction to benzodiazepines
SG42329A1 (en) Use of phenylcyclohexylcarboxamides
PL326490A1 (en) Treatment of traumatic brain injuries
GB9502136D0 (en) Treatment of waste
GB9507825D0 (en) Method of treatment
GB2306954B (en) Treatment of contaminated water
GB9504444D0 (en) Treatment of eczema
GB9503200D0 (en) Methods of treatment
ZA957904B (en) Treatment of water
GB9511633D0 (en) Treatment of water
GB9701448D0 (en) Methods of treatment
GB9602404D0 (en) Methods of treatment
GB9418898D0 (en) Treatment of water
GB9418899D0 (en) Treatment of water
GB9414421D0 (en) Treatment of water
GB9606457D0 (en) Treatment of coccidiosis
GB9518723D0 (en) Treatment of coccidiosis
ZA964220B (en) Treatment of wastewater
GB9502514D0 (en) Method of treatment
GB9508963D0 (en) Method of treatment

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired